3-amino-1-(2-morpholinoethyl)-quinoxalin-2(1H)-one | 847460-97-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-amino-1-(2-morpholinoethyl)-quinoxalin-2(1H)-one
• 英文别名: 3-Amino-1-[2-(4-morpholinyl)ethyl]-2(1h)-quinoxalinone；3-amino-1-(2-morpholin-4-ylethyl)quinoxalin-2-one
• CAS: 847460-97-3
• 化学式: C₁₄H₁₈N₄O₂
• 分子量: 274.323
• InChiKey: BBICIHNIBBUXTB-UHFFFAOYSA-N

物化性质

• 沸点：
  476.7±55.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  71.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-amino-1-(2-morpholinoethyl)-quinoxalin-2(1H)-one 、 3-氯苯甲酰氯 以 吡啶 为溶剂， 反应 2.0h， 以58%的产率得到3-chloro-N-(1,2-dihydro-1-(2-morpholinoethyl)-2-oxoquinoxalin-3-yl)benzamide
  参考文献：
  名称：

  [EN] HETEROCYCLIC CANNABINOID CB2 RECEPTOR ANTAGONISTS
  [FR] NOUVEAUX AGONISTES DES RECEPTEURS CANNABINOIDES CB2 ET UTILISATIONS DESDITS AGONISTES

  摘要：

  公开号：

  WO2005021547A3
• 作为产物：
  描述：

  tert-butyl 1,2-dihydro-1-(2-morpholinoethyl)-2-oxoquinoxalin-3-ylcarbamate 在 三氟乙酸 作用下， 反应 0.5h， 生成 3-amino-1-(2-morpholinoethyl)-quinoxalin-2(1H)-one
  参考文献：
  名称：

  [EN] HETEROCYCLIC CANNABINOID CB2 RECEPTOR ANTAGONISTS
  [FR] NOUVEAUX AGONISTES DES RECEPTEURS CANNABINOIDES CB2 ET UTILISATIONS DESDITS AGONISTES

  摘要：

  公开号：

  WO2005021547A3

文献信息

• [EN] NOVEL CANNABINOID CB2 RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] NOUVEAUX AGONISTES DES RECEPTEURS CANNABINOIDES CB2 ET UTILISATIONS DESDITS AGONISTES
  申请人：PHARMAXIS PTY LTD

  公开号：WO2005021547A2

  公开（公告）日：2005-03-10

  Novel selective cannabinoid CB2 receptor ligands, primarily agonists, have a number of biological and pharmacological activities, including bronchial action, immunomodulatory action and analgesia. Hence, they are useful for treating diseases or conditions characterized by pain, inflammation and immunological dysregulation. Examples of this class of novel compounds are 4 chloro-N-[1-(2-morpholin-4-ylethyl)-1H-benzimidazol-2-yl]benzamide and 4-chloro-N-[7 methoxy-1-(2-morpholin-4-ylethyl)-1H-benzimidazol-2-yl]benzamide. Other examples of the novel compounds are 4-derivatives of 3-amino and 3-carboxy-1,2-dihydro-1-substitutedquinazol-2-ones, including 2-chloro-N (1,2-dihydro-1-(2-morpholinoethyl)-2-oxoquinoxalin-3-yl)benzamide, 3-chloro-N-(1,2-dihydro-1-(2-morpholinoethyl)-2-oxoquinoxalin-3-yl)benzamide, tert-butyl 1,2-dihydro-1-(2-morpholinoethyl)-2-oxoquinoxalin-3-ylcarbamate and N-benzyl-3,4-dihydro-4-(2-morpholinoethyl)-3-oxoquinoxaline-2-carboxamide. The compounds bind specifically to a cell-bound or cell-free CB2 receptor with an affinity (Kd) ≤ 100 µM. As agonists, these compounds stimulate a CB2-related post-binding signal transduction event, e.g., inhibition of adenylyl cyclase activity, after binding to a CB2 receptor on a cell. These compounds are used to treat inflammatory conditions, cell proliferative disorders, or an immune disorder, and may be administered in combination with agents that are also useful for the treatment of the symptoms or cause of the underlying disease or condition.
• [EN] HETEROCYCLIC CANNABINOID CB2 RECEPTOR ANTAGONISTS<br/>[FR] NOUVEAUX AGONISTES DES RECEPTEURS CANNABINOIDES CB2 ET UTILISATIONS DESDITS AGONISTES
  申请人：PHARMAXIS PTY LTD

  公开号：WO2005021547A3

  公开（公告）日：2005-08-18